Table 2.
Combination therapy.
| Degradation by | Regulatory signal | Therapy | Cancer types | Reference |
|---|---|---|---|---|
| Proteasome | EGFR/GSK3β/β-TrCP | Gefitinib + anti-PD-1 | Colon cancer, TNBC | 13 |
| Proteasome | NFκB/CSN5 | Curcumin + anti-CTLA4 | TNBC, colon cancer, melanoma | 22 |
| Proteasome | AMPK | Metformin + CTLA4 | Breast cancer, lung cancer | 21 |
| Proteasome | EMT/β-catenin/STT3 | Etoposide + anti-Tim-3 | Colon cancer, TNBC | 23 |
| Lysosome | EGFR/B3GNT3 | STM108-MMAE conjugate | TNBC | 31 |
| Lysosome | CMTM6 | H1A + cisplatin | Breast cancer, colon cancer | 30 |
| Proteasome | CDK4/6/ cullin3SPOP | Palbociclib + anti-PD-1 | Colon cancer | 11 |